Pharma BD Deal Intelligence
Susquehanna's Andrew Finkelstein said the deal would give Actavis 'an earnings jolt' starting next year; Morningstar's Michael Waterhouse: 'we're probably not…
Actavis is buying Warner Chilcott in an all-stock deal valued at about $8.5 billion that would create the third-biggest specialty pharmaceutical company in the…
FTC consent order required divestiture of overlapping products including oral contraceptive Lo Loestrin Fe generic equivalents to remedy competitive concerns —…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Actavis acquired Warner Chilcott in a stock-for-stock transaction valued at approximately $8.5 billion, creating Actavis plc, an Ireland-domiciled specialty pharmaceutical company with roughly $11 billion in pro forma revenue. The transaction established the Irish tax-inversion structure later used for the Forest Laboratories acquisition.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Actavis plc / Warner Chilcott plc (this deal) | 2013 | $8.5B | 63 |
| Actavis plc / Forest Laboratories, Inc. | 2014 | $25.0B | 75 |
| Actavis plc / Allergan plc | 2014 | $70.5B | 61 |
| Ciba-Geigy AG / Sandoz AG | 1996 | $36.3B | 98 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
← Browse all deals · How we score deals
More: 2013 deals · Actavis plc deals · Dermatology deals